SCHEMBL162174

SCHEMBL162174

CCNC(=O)c1nc(O)co1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 2/20 0.38
HDAC6 Q9UBN7 2/20 0.38
KDM4E B2RXH2 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HDAC1 Q13547 1/20 0.35
HPGD P15428 2/20 0.34
CNR1 P21554 1/20 0.34
NPC1 O15118 1/20 0.34
PIN1 Q13526 1/20 0.33
CYP2C19 P33261 2/20 0.33
HPGDS O60760 1/20 0.32
ALOX15 P16050 1/20 0.32
GAA P10253 1/20 0.32
MAPT P10636 2/20 0.32
MMP1 P03956 1/20 0.31
MMP2 P08253 1/20 0.31
MMP3 P08254 1/20 0.31
MMP9 P14780 1/20 0.31
MMP8 P22894 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL162173 0.82 KDM4E (0.37) HDAC4HDAC6KDM4ENPSR1HSD17B10
SCHEMBL162569 0.81 HTT (0.44) HDAC4KDM4ENPSR1HSD17B10HPGD
SCHEMBL162863 0.77 SMN1; SMN2 (0.46) KDM4EHSD17B10NPC1MAPTMMP1
SCHEMBL164300 0.75 MLYCD (0.38) HDAC4KDM4ENPSR1HPGDCNR1
SCHEMBL158298 0.75 POLB (0.37) KDM4EHSD17B10HPGDCNR1GAA
SCHEMBL164834 0.70
SCHEMBL6613705 0.69 FAAH (0.43) HDAC4HDAC6HDAC1
SCHEMBL30586797 0.69 CES1 (0.38) HDAC4HDAC6KDM4ENPSR1HSD17B10
SCHEMBL164299 0.69 POLB (0.44) KDM4EHPGDNPC1GAAMMP1
SCHEMBL164108 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9856210-B2 Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis KYOTO UNIVERSITY (JP) 2018-01-02 US disclosed
EP-2611437-B1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS UNIV KYOTO (JP) 2017-03-29 EP disclosed
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2013-08-29 US disclosed
EP-2611437-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Kyoto University (JP) 2013-07-10 EP disclosed
WO-2012029994-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS SMN1; SMN2, SOD1, SOD3 HDAC4 2500/4885HDAC6 939/4885KDM4E 2214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.